Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-04-23

FDA Approved: NARATRIPTAN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Naratriptan filed by Hikma Pharmaceuticals USA Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Naratriptan (Naratriptan)

Snippet

SUPPL AP for NARATRIPTAN (NARATRIPTAN)